SAGE Therapeutics Inc at Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit (Virtual) Transcript
Hi, everyone. Thanks for joining us this afternoon for the Sage fireside chat here at Cowen's first Annual Neuropsychiatry Summit. I'm covering analyst, Ritu Baral. And joining us from Sage is CEO, Barry Greene, and long-standing CMO, Steve Kanes, who most of you know.
So thanks, everyone, for joining us. E-mail me any questions as we go along or submit them in the chat.
Questions & Answers
I guess zuranolone is going to be the main focus of this conference. We've been focused on depression and PTSD all day. Steve, can you -- just as a reminder, sort of briefly take us through zuranolone mechanism. And I think we've all heard this, but one of the biggest criticisms of the mechanism and especially in terms of your most recent data was, from the investor side, how is this mechanism not just in benzo. So as you take us through the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |